Staidson (Beijing) Biopharmaceuticals Co., Ltd. – Trademark Portfolio
Entity Type: 99
Staidson (Beijing) Biopharmaceuticals Co., Ltd. holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. Currently, 4 trademarks are registered and 2 are pending. Notable registered marks include GOXBLEM, STAIDSON, and ZAGBEMIZ. The owner is based in Beijing.
Beijing Econ. & Tech. Development Zone
No. 36, Jinghai Second Road
Beijing , CN
Showing of trademarks Trademarks
Trademark Classifications
Staidson (Beijing) Biopharmaceuticals Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Staidson (Beijing) Biopharmaceuticals Co., Ltd. have?
Staidson (Beijing) Biopharmaceuticals Co., Ltd. has 8 U.S. trademarks filed with the USPTO. Of these, 4 registered, 2 pending, 2 cancelled.
What trademark classes does Staidson (Beijing) Biopharmaceuticals Co., Ltd. file in?
Staidson (Beijing) Biopharmaceuticals Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Staidson (Beijing) Biopharmaceuticals Co., Ltd.'s most well-known trademarks?
Staidson (Beijing) Biopharmaceuticals Co., Ltd.'s registered trademark portfolio includes well-known marks such as GOXBLEM, STAIDSON, and ZAGBEMIZ. These are among 4 currently registered trademarks in the portfolio.
What is Staidson (Beijing) Biopharmaceuticals Co., Ltd.'s trademark registration success rate?
Staidson (Beijing) Biopharmaceuticals Co., Ltd. has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 2 applications are pending review.